ReviewFrontiers in immunology2026

HDAC3-driven immunometabolic reprogramming in type 2 diabetes and its complications: from enzymatic deacetylation to non-enzymatic scaffolding.

Nianxin Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.